// App-Quantinova.ai

2958 : A cancer-specific monoclonal antibody against podocalyxin developed by CasMab technology inhibited the tumor growth by antibody-dependent cellular cytotoxicity

Researchers

Presenter

  • Yukinari Kato

Principal Investigators

  • Satoshi Ogasawara

  • Akiko Kunita

  • Yuki Fujii

  • Mika K. Kaneko

Medical Centers

  • Tohoku University, Miyagi, Japan

  • The University of Tokyo, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Glioblastoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved